CIK 0001527599 · Non-accelerated filer<br>Smaller reporting company
SYNLOGIC, INC.
Sign in to watch- Ticker
- SYBX
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 261824804
- Phone
- 617-659-2802
- Business address
- PO BOX 30, WINCHESTER, MA, 01890
- Former names
- Mirna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 94 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-27 | New Enterprise Associates 14, L.P. Director | Other disposition · Warrants (Right to Buy) | −2,640,845 | 0 | ||
| 2026-07-27 | New Enterprise Associates 14, L.P. Director | Purchase · Warrants (Right to Buy) | +2,640,845 | 2,640,845 | ||
| 2025-10-29 | Dooley Mary Beth See Remarks below | Sale | −157 | $1.81 | $284 | 12,744 |
| 2025-04-26 | Shea Richard P Director | Grant or award | +15,000 | 15,506 | ||
| 2025-04-26 | Flynn James P Director | Grant or award | +15,000 | 15,000 | ||
| 2025-04-02 | Dooley Mary Beth See Remarks below | Sale | −144 | $1.20 | $173 | 12,901 |
| 2025-02-03 | Dooley Mary Beth See Remarks below | Sale | −2,107 | $1.33 | $3K | 13,045 |
| 2024-10-29 | Dooley Mary Beth Head of Finance | Sale | −79 | $1.40 | $111 | 15,152 |
| 2024-04-02 | Dooley Mary Beth Head of Finance | Sale | −188 | $1.73 | $325 | 15,231 |
| 2024-04-02 | Awad Antoine Chief Operating Officer | Sale | −372 | $1.73 | $644 | 33,859 |
| 2024-03-19 | Flynn James P Director | Grant or award · Stock Option (right to buy) | +4,000 | 4,000 | ||
| 2024-01-02 | Hurter Patricia N. Director | Grant or award · Stock Option (right to buy) | +14,678 | 14,678 | ||
| 2024-01-02 | Barrett Peter Director | Grant or award · Stock Option (right to buy) | +24,923 | 24,923 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −5,591 | 0 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −3,733 | 0 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −3,600 | 0 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −9,999 | 0 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −12,332 | 0 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −12,352 | 0 | ||
| 2023-11-10 | Brennan Aoife President and CEO | Returned to the company · Stock Option (right to buy) | −18,999 | 0 |
Page 1 of 8 · 152 trades